2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Transplantation, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

1863 Improved risk stratification beyond the Burkitt lymphoma international prognostic index in adult Burkitt lymphoma: A multicenter real-world study

Jinuo Wang, MD, Xiaoyu Cao2, Feiteng Huang3, Xiaoyan Liu4, Jifu Zheng5, Junyu Zhang6, Yi Zhao7, Wenjun Wu, MD8, Jian Yu9, Zhen Cai, MD,PhD10
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 The First Affiliated Hospital of Zhengzhou University, Hangzhou, China
5 The Second Affiliated Hospital of Nanchang University, Nanchang, China
6 Lishui Central Hospital, Lishui, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background: Burkitt lymphoma (BL) is an exceptionally aggressive B-cell malignancy with heterogeneous outcomes despite intensive immunochemotherapy. The Burkitt lymphoma International Prognostic Index (BL-IPI) was developed primarily from Western cohorts, and its applicability in Chinese patients remains unclear. Furthermore, the prognostic significance of genomic alterations in BL is not fully established. We aimed to define clinical and molecular predictors of survival and develop an optimized risk stratification model for adult BL.

 

Methods: We retrospectively analyzed 131 adults with BL diagnosed between 2015 and 2025 across five Chinese centers. Clinical characteristics, treatment data, and next-generation sequencing (NGS) results were collected. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier analysis. Independent prognostic factors were identified using Cox proportional hazards regression. A modified BL-IPI (aBL-IPI) was developed based on multivariate predictors and compared with the original BL-IPI using receiver operating characteristic (ROC) analysis.

 

Results: After a median follow-up of 38.2 months, median OS and PFS were 47.1 and 33.5 months, respectively. Univariate analysis identified age ≥40 years (HR, 1.78; P=0.046), ECOG performance status ≥2 (HR, 4.97; P<0.001), LDH ≥500 U/L (HR, 3.66; P<0.001), β2-microglobulin >3.0 mg/L (HR, 2.76; P=0.003), central nervous system (CNS) involvement (HR, 9.77; P<0.001), bone marrow involvement (HR, 4.04; P<0.001), hepatosplenic involvement (HR, 4.68; P<0.001), gastrointestinal involvement (HR, 1.94; P=0.017), and bilateral diaphragmatic lymph node involvement (HR, 3.64; P<0.001) as adverse prognostic factors for OS. CNS prophylaxis was associated with improved survival (HR, 0.42; P=0.003).

Multivariate analysis identified elevated LDH (HR, 6.29; P=0.002), CNS involvement (HR, 4.74; P=0.012), and hepatosplenic involvement (HR, 4.20; P=0.008) as independent predictors of inferior OS. NGS revealed TP53 mutations as the most frequent alteration (44.2%), which were strongly associated with poor outcomes (HR, 10.70; P<0.001). Two-year OS and PFS were markedly inferior in TP53-mutated patients compared with TP53 wild-type patients (OS: 49.9% vs 95.8%; PFS: 39.1% vs 87.5%).

Based on independent clinical predictors, we developed the aBL-IPI incorporating age ≥40 years (1 point), ECOG ≥2 (1 point), CNS involvement (2 points), hepatosplenic involvement (2 points), and LDH ≥500 U/L (2 points). Patients were classified into low-risk (0–1), intermediate-risk (2–4), and high-risk (≥5) groups, with significantly different OS outcomes (P<0.001). ROC analysis demonstrated improved discrimination of aBL-IPI compared with BL-IPI (AUC, 0.774 [95% CI, 0.688–0.861] vs 0.710 [95% CI, 0.616–0.804]). When both models were included in multivariate analysis, aBL-IPI remained independently associated with OS (P<0.001), whereas BL-IPI lost significance (P=0.601).

 

Conclusions: In this multicenter Chinese cohort, CNS involvement, hepatosplenic involvement, and elevated LDH were independent predictors of inferior survival in adult BL. TP53 mutations identified a genetically defined high-risk subgroup with markedly poor outcomes. The proposed aBL-IPI improved prognostic discrimination compared with the original BL-IPI and may provide a practical tool for individualized risk stratification in adult BL. Prospective external validation is warranted.

Jinuo Wang, MD: No relevant conflicts of interest to declare.